Alessio Molinari

A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein Inhibitor

Anna Lucia Fallacara, Claudio Zamperini, Ana Podolski-Renić et al. · Cancers · 2019 · 43 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Hematopoietic cell kinase (HCK) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin/PI3K pathway and regulation of erythropoiesis

Fernanda Marconi Roversi, Fernando Vieira Pericole, João Agostinho Machado‐Neto et al. · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 2016 · 35 citations · Full text

Medicine, Cell Biology, Hematology +13

Prodrugs of Pyrazolo[3,4-<i>d</i>]pyrimidines: From Library Synthesis to Evaluation as Potential Anticancer Agents in an Orthotopic Glioblastoma Model

Giulia Iovenitti, Claudio Zamperini, Federica Coniglio et al. · Journal of Medicinal Chemistry · 2017 · 35 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment

Alessio Molinari, Anna Lucia Fallacara, Salvatore Di Maria et al. · Bioorganic & Medicinal Chemistry Letters · 2018 · 28 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +14

AuNP Pyrazolo[3,4-<i>d</i>]pyrimidine Nanosystem in Combination with Radiotherapy against Glioblastoma

Alessio Molinari, Giulia Iovenitti, Arianna Mancini et al. · ACS Medicinal Chemistry Letters · 2020 · 14 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +17